Диагностические и прогностические возможности электрохимических измерений редокс потенциала плазмы крови

Aims: Determination of operating characteristics of the test based on blood plasma redox potential monitoring in patients with different pathological conditions associated with impaired oxygen metabolism during treatment in postoperative period and expanding the range of parameters of the developed method of investigation of blood plasma redox potential.Methods: It were examined healthy volunteers group as following group (n =63), groups of patients with transplanted liver (n =64), kidney (n =59), and lungs (n =7). Redox potential measurements were done by platinum electrode, reference electrode was silver-chlorine one. Potentiostate IPC-ProL was used to registrate and record a dependence redox potential via time. Time of measurement was 15 min.Results: statistically significant differencees of redox potentials ranges was found in healthy volunteers and patients with transplanted kidney and liver. Ratio of measured redox potentials coincident with the values within the confidence interval in healthy volunteers was 12% in patients with transplanted kidney and 10% in patients with transplanted liver. We observed significant differences in the nature of changes of blood plasma's redox potential values in course of monitoring of subgroups of patients with and without complications after liver transplantation. It was found that sensitivity of electrochemical method was 85%, selectivity — 69,8%, precision — 85,2%.Conclusion: we discovered value ranges of blood plasma redox potential typical for different pathological states; we detected an interaction between the effect of treatment and quantitative changes in the values of the blood plasma redox potentials; criterion for early predicition of complications in patients with transplanted liver was proposed basing on redox potential monitoring during postoperative period.Цель исследования: определение операционных характеристик теста на основе мониторинга величин редокс-потенциала плазмы крови пациентов с различными патологическими состояниями, сопровождающимися нарушениями кислородного обмена в процессе лечения; расширение спектра параметров разработанного нами метода исследования редокс-потенциала плазмы крови.Методы: обследованы группы практически здоровых добровольцев (n =63) и пациентов со следующими патологиями: с трансплантацией почки (n =59), печени (n =64) и легкого (n =7). Измерения редокс-потенциала проводили на платиновом микроэлектроде относительно насыщенного хлорсеребряного электрода сравнения. Потенциостат IPC-Pro L (НПФ «Вольта») был использован для записи зависимостей потенциала от времени. Время регистрации составляло 15 мин.Результаты: обнаружены статистически достоверные различия в диапазонах величин редокс-потенциала для практически здоровых людей и пациентов с трансплантированными почкой и печенью. Доля измеренных величин редокс-потенциалов, совпадающих с величинами, находящимися в пределах доверительного интервала редокс-потенциалов практически здоровых людей, составила 12% для пациентов с трансплантированной почкой и 10% для пациентов с трансплантированной печенью. Обнаружено существенное различие в характере изменений величин редокс-потенциала плазмы крови при мониторинге подгрупп пациентов с наличием и отсутствием осложнений после трансплантации печени. Найдено, что чувствительность электрохимического метода определения величин редокс-потенциала плазмы крови составила 85,7%, специфичность — 69,8%, точность — 85,2%.Заключение: обнаружены диапазоны величин редокс-потенциала плазмы крови, характерные для различных патологических состояний; установлена связь эффекта проводимого лечения с количественными изменениями величин редокс-потенциала плазмы крови пациента; предложен критерий для раннего прогнозирования осложнений у пациентов с трансплантированной печенью на основе мониторинга редокс-потенциала в послеоперационном периоде.

The PHENIX Experiment at RHIC

The physics emphases of the PHENIX collaboration and the design and current status of the PHENIX detector are discussed. The plan of the collaboration for making the most effective use of the available luminosity in the first years of RHIC operation is also presented.Comment: 5 pages, 1 figure. Further details of the PHENIX physics program available at http://www.rhic.bnl.gov/phenix

ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition

ALK-positive histiocytosis is a rare subtype of histiocytic neoplasm first described in 2008 in three infants with multisystemic disease involving the liver and hematopoietic system. This entity has subsequently been documented in case reports and series to occupy a wider clinicopathologic spectrum with recurrent KIF5B-ALK fusions. The full clinicopathologic and molecular spectra of ALK-positive histiocytosis remain, however, poorly characterized. Here, we describe the largest study of ALK-positive histiocytosis to date, with detailed clinicopathologic data of 39 cases, including 37 cases with confirmed ALKrearrangements. The clinical spectrum comprised distinct clinical phenotypic groups: infants with multisystemic disease with liver and hematopoietic involvement, as originally described (Group 1A: 6/39), other patients with multisystemic disease (Group 1B: 10/39), and patients with single-system disease (Group 2: 23/39). Nineteen patients of the entire cohort (49%) had neurologic involvement (seven and twelve from Groups 1B and 2, respectively). Histology included classic xanthogranuloma features in almost one third of cases, whereas the majority displayed a more densely cellular, monomorphic appearance without lipidized histiocytes but sometimes more spindled or epithelioid morphology. Neoplastic histiocytes were positive for macrophage markers and often conferred strong expression of phosphorylated-ERK, confirming MAPK pathway activation. KIF5B-ALK fusions were detected in 27 patients, while CLTC-ALK, TPM3-ALK, TFG-ALK, EML4-ALK and DCTN1-ALK fusions were identified in single cases. Robust and durable responses were observed in 11/11 patients treated with ALK inhibition, ten with neurologic involvement. This study presents the existing clinicopathologic and molecular landscape of ALK-positive histiocytosis, and provides guidance for the clinical management of this emerging histiocytic entity.Molecular tumour pathology - and tumour genetic

Dynamics of two dipole-coupled superconducting qubits interacting with two independent coplanar resonators

В рамках двойной модели Джейнса-Каммингса исследована динамика атом-атомного перепутывания двух дипольно-связанных сверхпроводящих кубитов, нерезонансно взаимодействующих с двумя независимыми модами резонаторных полей. Показано, что для сепарабельных начальных состояний кубитов расстройка влияет только на период осцилляций параметра перепутывания, а не на его максимальное значение. Установлено также, что максимальная степень перепутывания кубитов достигается в случае равных констант кубит-полевого взаимодействия. Within the frameework of the double Jaynes-Cummings model, the dynamics of the atom-atom entanglement of two dipole-coupled superconducting qubits interacting nonresonantly withn two independent modes of the resonator fields was investigated. It is shown that for a separable initial states of qubits, the detuning affects only the period of entanglement oscillations, not the maхimum value of entanglement. It was also established that for considered model the maximal amount of entanglement takes place for equal atomfield couplings

ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition

ALK-positive histiocytosis is a rare subtype of histiocytic neoplasm first described in 2008 in 3 infants with multisystemic disease involving the liver and hematopoietic system. This entity has subsequently been documented in case reports and series to occupy a wider clinicopathologic spectrum with recurrent KIF5B-ALK fusions. The full clinicopathologic and molecular spectra of ALK-positive histiocytosis remain, however, poorly characterized. Here, we describe the largest study of ALK-positive histiocytosis to date, with detailed clinicopathologic data of 39 cases, including 37 cases with confirmed ALK rearrangements. The clinical spectrum comprised distinct clinical phenotypic groups: infants with multisystemic disease with liver and hematopoietic involvement, as originally described (Group 1A: 6/39), other patients with multisystemic disease (Group 1B: 10/39), and patients with single-system disease (Group 2: 23/39). Nineteen patients of the entire cohort (49%) had neurologic involvement (7 and 12 from Groups 1B and 2, respectively). Histology included classic xanthogranuloma features in almost one-third of cases, whereas the majority displayed a more densely cellular, monomorphic appearance without lipidized histiocytes but sometimes more spindled or epithelioid morphology. Neoplastic histiocytes were positive for macrophage markers and often conferred strong expression of phosphorylated extracellular signal-regulated kinase, confirming MAPK pathway activation. KIF5B-ALK fusions were detected in 27 patients, whereas CLTC-ALK, TPM3-ALK, TFG-ALK, EML4-ALK, and DCTN1-ALK fusions were identified in single cases. Robust and durable responses were observed in 11/11 patients treated with ALK inhibition, 10 with neurologic involvement. This study presents the existing clinicopathologic and molecular landscape of ALK-positive histiocytosis and provides guidance for the clinical management of this emerging histiocytic entity.NEUROPatholog

ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition

ALK-positive histiocytosis is a rare subtype of histiocytic neoplasm first described in 2008 in 3 infants with multisystemic disease involving the liver and hematopoietic system. This entity has subsequently been documented in case reports and series to occupy a wider clinicopathologic spectrum with recurrent KIF5B-ALK fusions. The full clinicopathologic and molecular spectra of ALK-positive histiocytosis remain, however, poorly characterized. Here, we describe the largest study of ALK-positive histiocytosis to date, with detailed clinicopathologic data of 39 cases, including 37 cases with confirmed ALK rearrangements. The clinical spectrum comprised distinct clinical phenotypic groups: infants with multisystemic disease with liver and hematopoietic involvement, as originally described (Group 1A: 6/39), other patients with multisystemic disease (Group 1B: 10/39), and patients with single-system disease (Group 2: 23/39). Nineteen patients of the entire cohort (49%) had neurologic involvement (7 and 12 from Groups 1B and 2, respectively). Histology included classic xanthogranuloma features in almost one-third of cases, whereas the majority displayed a more densely cellular, monomorphic appearance without lipidized histiocytes but sometimes more spindled or epithelioid morphology. Neoplastic histiocytes were positive for macrophage markers and often conferred strong expression of phosphorylated extracellular signal-regulated kinase, confirming MAPK pathway activation. KIF5B-ALK fusions were detected in 27 patients, whereas CLTC-ALK, TPM3-ALK, TFG-ALK, EML4-ALK, and DCTN1-ALK fusions were identified in single cases. Robust and durable responses were observed in 11/11 patients treated with ALK inhibition, 10 with neurologic involvement. This study presents the existing clinicopathologic and molecular landscape of ALK-positive histiocytosis and provides guidance for the clinical management of this emerging histiocytic entity